Michael Barbella, Managing Editor08.26.22
Biomedical Bonding AB has secured an additional patent in China based on a unique primer formulation for use with its resin-based composite technology directly on wet bone substrates or metal implants.
The patent in China is an important step toward the commercialization of BMB’s Bonevolent line of products the company claims will introduce a new paradigm in bone fracture fixation. The Bonevolent technology has the advantage of being customizable by the surgeon and enables patient-specific adaptation to the fracture and bone geometry. The technology also contains a biocompatible substance that does not cause any irritation or soft tissue adhesion—a common issue with metal implants leading to patient discomfort and post-surgery complications.
“BMB continuous to expand its Bonevolent IPR portfolio in key geographical positions in which China is considered as an attractive market for the company’s fracture fixation products. With this patent approved, the IPR for our primer technology is further strengthened as it protects all key components facilitating exceptional resins-based fixation of bones, metal or teeth. As a company, such approval is a crucial element and allows BMB to pursue the commercialization of its composite-based fixators towards patient-customized treatment of both bone fractures as well dental restorations,” Biomedical Bonding Founder and CEO Prof. Michael Malkoch said.
Biomedical Bonding AB is a platform-based medtech company that develops medical adhesive fixators and surgical methodologies with focus on hard tissue restorations. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent products are easy to use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole, according to the company. BMB is a privately held company headquartered in Stockholm, Sweden.
The patent in China is an important step toward the commercialization of BMB’s Bonevolent line of products the company claims will introduce a new paradigm in bone fracture fixation. The Bonevolent technology has the advantage of being customizable by the surgeon and enables patient-specific adaptation to the fracture and bone geometry. The technology also contains a biocompatible substance that does not cause any irritation or soft tissue adhesion—a common issue with metal implants leading to patient discomfort and post-surgery complications.
“BMB continuous to expand its Bonevolent IPR portfolio in key geographical positions in which China is considered as an attractive market for the company’s fracture fixation products. With this patent approved, the IPR for our primer technology is further strengthened as it protects all key components facilitating exceptional resins-based fixation of bones, metal or teeth. As a company, such approval is a crucial element and allows BMB to pursue the commercialization of its composite-based fixators towards patient-customized treatment of both bone fractures as well dental restorations,” Biomedical Bonding Founder and CEO Prof. Michael Malkoch said.
Biomedical Bonding AB is a platform-based medtech company that develops medical adhesive fixators and surgical methodologies with focus on hard tissue restorations. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent products are easy to use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole, according to the company. BMB is a privately held company headquartered in Stockholm, Sweden.